Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“Early View | Haematologica
Phase 1 study (Blinatumomab post alloHCT for 2 cycles among patients in CR2 (children and young adults) ALL
Most of the G4 toxicities were hematological.
Almost all patients received Blinatumomab pre-alloHCT.”
More posts featuring Blinatumomab.